Table 3.
Adverse events.
| Fast Metabolizers (n = 17) | Slow Metabolizers (n = 17) | p-Value | |
|---|---|---|---|
| DGF | 4 (24%) | 5 (29%) | 1 a |
| Antibodies and rejection | |||
| Preformed Class II DSA | 1 (6%) | 1 (6%) | 1 a |
| Class II DSA before conversion | 1 (6%) | 1 (6%) | 1 a |
| Class I DSA after conversion | 1 (6%) | 0 | 1 a |
| BPAR before conversion to EVR | |||
| AMR | 1 (6%) | 1 (6%) | 0.490 b |
| TCMR | 1 (6%) | 2 (12%) | |
| Combined AMR + TCMR | 7 (41%) | 3 (18%) | |
| BPAR after conversion to EVR | |||
| AMR | 0 | 0 | 0.485 a |
| TCMR | 2 (12%) | 0 | |
| Combined AMR + TCMR | 0 | 1 (6%) | |
| Infections | |||
| CMV infection before conversion | 2 (12%) | 4 (24%) | 0.656 a |
| CMV infection after conversion | 1 (6%) | 0 | 1 a |
| BKV infection before conversion | 2 (12%) | 1 (6%) | 1 a |
| BKV infection after conversion | 0 | 0 | - |
| Death | 0 | 1 (6%) | 1 a |
DGF, delayed graft function; DSA, donor-specific antibody; BPAR, biopsy-proven acute rejection; AMR, antibody-mediated rejection; TCMR, T-cell mediated rejection; EVR, everolimus. Statistics: Adverse events are reported as absolute and relative frequencies. a Fisher’s exact test.